目的 探討葛酮通絡(luò)膠囊聯(lián)合丁苯酞氯化鈉注射液治療急性腦梗死的臨床療效。方法 選取2017年5月—2018年5月在淮南市第一人民醫(yī)院進(jìn)行治療的86例急性腦梗死患者作為研究對(duì)象，根據(jù)用藥不同將患者分為對(duì)照組（43例）和治療組（43例）。對(duì)照組靜脈滴注丁苯酞氯化鈉注射液，100 mL/次，2次/d；治療組在對(duì)照組治療的基礎(chǔ)上口服葛酮通絡(luò)膠囊，0.5 g/次，2次/d。兩組患者均連續(xù)治療2周。觀察兩組患者的臨床療效，比較兩組治療前后的美國(guó)國(guó)立衛(wèi)生研究卒中量表（NIHSS）評(píng)分、改良Rankin評(píng)分（mRS）、蒙特利爾認(rèn)知評(píng)估量表法（MoCA）評(píng)分、血清學(xué)指標(biāo)和腦血流動(dòng)力學(xué)指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組有效率分別為81.40%和97.67%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者NIHSS評(píng)分、mRS評(píng)分顯著降低，MoCA評(píng)分顯著升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后治療組評(píng)分顯著優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清超敏C反應(yīng)蛋白（hs-CRP）、可溶性腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體（sTRAIL）、單核細(xì)胞趨化蛋白-1（MCP-1）、新喋呤（Npt）水平均明顯降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后治療組血清學(xué)指標(biāo)水平明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組平均血流量（Q_mean）、平均血流速度（V_mean）均顯著升高，動(dòng)態(tài)阻抗（DR）、腦血管特性阻抗（ZCV）和腦血管外周阻力（R）均顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后治療組腦血流動(dòng)力學(xué)指標(biāo)明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 葛酮通絡(luò)膠囊聯(lián)合丁苯酞氯化鈉注射液治療急性腦梗死可有效改善細(xì)胞因子水平，促進(jìn)神經(jīng)功能恢復(fù)，改善腦血流動(dòng)力學(xué)指標(biāo)、日?；顒?dòng)能力和認(rèn)知能力，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Getong Tongluo Capsules combined with Butylphthalide and Sodium Chloride Injection in treatment of acute cerebral infarction. Methods Patients (86 cases) with acute cerebral infarction in Huainan First People's Hospital from May 2017 to May 2018 were randomly divided into control (43 cases) and treatment (43 cases) groups according to different drugs. Patients in the control group were iv administered with Butylphthalide and Sodium Chloride Injection, 100 mL/time, twice daily. Patients in the treatment group were po administered with Getong Tongluo Capsules, 0.5 g/time, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the NIHSS scores, mRS scores, MoCA scores, serological indexes, and cerebral hemodynamic indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.40% and 97.67%, respectively, and there was difference between two groups (P<0.05). After treatment, the NIHSS and mRS scores in two groups were significantly decreased, but MoCA scores were significantly increased, and the difference was statistically significant in the same group (P<0.05). And those scores in the treatment group after treatment were significantly better those in the control group, with significant difference between two groups (P<0.05). After treatment, the serum levels of hs-CRP, sTRAIL, MCP-1, and Npt in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serological indexes in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, Q_mean and V_mean in two groups were significantly increased, but DR, ZCV, and R were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the cerebral hemodynamic indexes in the treatment group after treatment were significantly better those in the control group, with significant difference between two groups (P<0.05). Conclusion Getong Tongluo Capsules combined with Butylphthalide and Sodium Chloride Injection in treatment of acute cerebral infarction can effectively improve the cytokines level, promote the recovery of nerve function, and improve cerebral hemodynamics indicators, daily activity and cognitive ability, which has a certain clinical application value.